Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mercury BiopharmaceuticalROCO:6932 +6.96%31 Debt-to-Equity is 0.21 as of Jun. 2026, which is 11% above its 10-year median of 0.19. GuruFocus rates ROCO:6932 with a GF Score™ of 31/100 and a GF Value™ of NT$36.00 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 815 Drug Manufacturers companies, Mercury Biopharmaceutical ranks better than 58.28% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Mercury Biopharmaceutical's Debt-to-Equity or its related term are showing as below:
ROCO:6932'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.1 Med: 0.19 Max: 0.29
Current: 0.21
During the past 7 years, the highest Debt-to-Equity Ratio of Mercury Biopharmaceutical was 0.29. The lowest was 0.10. And the median was 0.19.
ROCO:6932's Debt-to-Equity is ranked better than 58.28% of 815
companies
in the Drug Manufacturers industry
Industry Median: 0.28
vs ROCO:6932: 0.21
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Mercury Biopharmaceutical Debt-to-Equity Related Terms
Mercury Biopharmaceutical Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Mercury Biopharmaceutical's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mercury Biopharmaceutical Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mercury Biopharmaceutical's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Mercury Biopharmaceutical's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mercury Biopharmaceutical (ROCO:6932) has a Debt-to-Equity of 0.21 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Mercury Biopharmaceutical and its competitors. This is 11% above median its historical median of 0.19. Over the past decade, Mercury Biopharmaceutical's Debt-to-Equity has ranged from 0.10 to 0.29. According to the industry distribution chart, Mercury Biopharmaceutical ranks #340 out of 815 companies in the Drug Manufacturers industry, placing it in the top 41.7%.
Is Mercury Biopharmaceutical's Debt-to-Equity too high?
Mercury Biopharmaceutical's current Debt-to-Equity of 0.21 is 11% above median its 10-year median of 0.19. Over the past 10 years, this metric has ranged from a low of 0.10 to a high of 0.29. The Drug Manufacturers industry median Debt-to-Equity is 0.28. Mercury Biopharmaceutical's value of 0.21 is 25% below this industry median. Based on the distribution chart, Mercury Biopharmaceutical ranks #340 out of 815 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Mercury Biopharmaceutical has a GF Score™ of 31/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mercury Biopharmaceutical's Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Mercury Biopharmaceutical ranks #340 out of 815 companies for Debt-to-Equity. This puts Mercury Biopharmaceutical in the upper half of its industry. The industry median Debt-to-Equity is 0.28. Mercury Biopharmaceutical's value of 0.21 is 25% below this benchmark. Historically, Mercury Biopharmaceutical's own Debt-to-Equity has ranged from 0.10 to 0.29 over the past decade. While the company's 10-year median is 0.19 vs. the industry median of 0.28, Mercury Biopharmaceutical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mercury Biopharmaceutical's current Debt-to-Equity of 0.21 is 25% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Mercury Biopharmaceutical and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mercury Biopharmaceutical's current Debt-to-Equity is 0.21, which is 11% above median its own 10-year median of 0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mercury Biopharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Mercury Biopharmaceutical (ROCO:6932) is currently considered Possible Value Trap. The stock's GF Value™ is NT$36.00, compared to a current price of NT$5.99 — trading 83.4% below its estimated fair value. The current Debt-to-Equity is 0.21, which is 11% above median its 10-year median of 0.19 and 25% below the Drug Manufacturers industry median of 0.28. Mercury Biopharmaceutical's overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Mercury Biopharmaceutical (ROCO:6932), the current Debt-to-Equity is 0.21 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mercury Biopharmaceutical (ROCO:6932) Overvalued in 2026?
Based on GuruFocus' analysis, Mercury Biopharmaceutical stock appears to be undervalued.
The current stock price of NT$5.99 is trading 83.4% below its estimated GF Value™ of NT$36.00.
GuruFocus considers Mercury Biopharmaceutical to be Possible Value Trap.
Key valuation signals for ROCO:6932:
Debt-to-Equity: 0.21 (11% above median its 10-year median of 0.19)
GF Value™: NT$36.00 vs. price of NT$5.99 (83.4% below fair value)
Industry Position: 25% below the Drug Manufacturers median (#340 of 815)
No single metric tells the full story. See the ROCO:6932 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mercury Biopharmaceutical Corp focuses on the development of drugs for unmet medical needs. It offers a development platform focusing on rapid release and free adjustable doses. Its 3D powder bonding method (binder jetting) combines powder and special molding adhesive and stacks them in layers.
31GF Score
Get the complete analysis for ROCO:6932
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6932 has been successfully added to your 
